» Articles » PMID: 23266198

Membrane-bound α-synuclein Interacts with Glucocerebrosidase and Inhibits Enzyme Activity

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2012 Dec 26
PMID 23266198
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in GBA, the gene encoding glucocerebrosidase, the lysosomal enzyme deficient in Gaucher disease increase the risk for developing Parkinson disease. Recent research suggests a relationship between glucocerebrosidase and the Parkinson disease-related amyloid-forming protein, α-synuclein; however, the specific molecular mechanisms responsible for association remain elusive. Previously, we showed that α-synuclein and glucocerebrosidase interact selectively under lysosomal conditions, and proposed that this newly identified interaction might influence cellular levels of α-synuclein by either promoting protein degradation and/or preventing aggregation. Here, we demonstrate that membrane-bound α-synuclein interacts with glucocerebrosidase, and that this complex formation inhibits enzyme function. Using site-specific fluorescence and Förster energy transfer probes, we mapped the protein-enzyme interacting regions on unilamellar vesicles. Our data suggest that on the membrane surface, the glucocerebrosidase-α-synuclein interaction involves a larger α-synuclein region compared to that found in solution. In addition, α-synuclein acts as a mixed inhibitor with an apparent IC(50) in the submicromolar range. Importantly, the membrane-bound, α-helical form of α-synuclein is necessary for inhibition. This glucocerebrosidase interaction and inhibition likely contribute to the mechanism underlying GBA-associated parkinsonism.

Citing Articles

Investigating the Impact of the Parkinson's-Associated GBA1 E326K Mutation on β-Glucocerebrosidase Dimerization and Interactome Dynamics Through an In Silico Approach.

Pietrafesa D, Casamassa A, Benassi B, Santoro M, Marano M, Consales C Int J Mol Sci. 2024; 25(21).

PMID: 39518995 PMC: 11870034. DOI: 10.3390/ijms252111443.


Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.

Zhang X, Wu H, Tang B, Guo J Transl Neurodegener. 2024; 13(1):48.

PMID: 39267121 PMC: 11391654. DOI: 10.1186/s40035-024-00437-6.


Interaction between α-Synuclein and Bioactive Lipids: Neurodegeneration, Disease Biomarkers and Emerging Therapies.

Sanluca C, Spagnolo P, Mancinelli R, De Bartolo M, Fava M, Maccarrone M Metabolites. 2024; 14(7).

PMID: 39057675 PMC: 11278689. DOI: 10.3390/metabo14070352.


Mutations in Glycosyltransferases and Glycosidases: Implications for Associated Diseases.

Gu X, Kovacs A, Myung Y, Ascher D Biomolecules. 2024; 14(4).

PMID: 38672513 PMC: 11048727. DOI: 10.3390/biom14040497.


Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases.

Moors T, Morella M, Bertran-Cobo C, Geut H, Udayar V, Timmermans-Huisman E Acta Neuropathol. 2024; 147(1):67.

PMID: 38581586 PMC: 10998821. DOI: 10.1007/s00401-024-02707-z.


References
1.
Chandra S, Chen X, Rizo J, Jahn R, Sudhof T . A broken alpha -helix in folded alpha -Synuclein. J Biol Chem. 2003; 278(17):15313-8. DOI: 10.1074/jbc.M213128200. View

2.
Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H . NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett. 1998; 239(1):45-8. DOI: 10.1016/s0304-3940(97)00891-4. View

3.
Norris E, Giasson B, Lee V . Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 2004; 60:17-54. DOI: 10.1016/S0070-2153(04)60002-0. View

4.
Ulmer T, Bax A, Cole N, Nussbaum R . Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem. 2004; 280(10):9595-603. DOI: 10.1074/jbc.M411805200. View

5.
Spillantini M, Schmidt M, Lee V, Trojanowski J, Jakes R, Goedert M . Alpha-synuclein in Lewy bodies. Nature. 1997; 388(6645):839-40. DOI: 10.1038/42166. View